Pangaea Financial Statements From 2010 to 2026
| PANG Stock | EUR 1.69 0.04 2.31% |
Check Pangaea Oncology financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Pangaea Oncology's main balance sheet or income statement drivers, such as , as well as many indicators such as . Pangaea financial statements analysis is a perfect complement when working with Pangaea Oncology Valuation or Volatility modules.
Pangaea |
Pangaea Oncology SA Company Return On Equity Analysis
Pangaea Oncology's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Pangaea Oncology Return On Equity | -44.97 |
Most of Pangaea Oncology's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Pangaea Oncology SA is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, Pangaea Oncology SA has a Return On Equity of -44.97. This is 87.61% higher than that of the Healthcare sector and notably higher than that of the Diagnostics & Research industry. The return on equity for all Spain stocks is notably higher than that of the company.
Pangaea Oncology Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Pangaea Oncology's current stock value. Our valuation model uses many indicators to compare Pangaea Oncology value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Pangaea Oncology competition to find correlations between indicators driving Pangaea Oncology's intrinsic value. More Info.Pangaea Oncology SA is considered to be number one stock in return on equity category among its peers. It also is considered to be number one stock in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Pangaea Oncology by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Pangaea Oncology's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.About Pangaea Oncology Financial Statements
Pangaea Oncology stakeholders use historical fundamental indicators, such as Pangaea Oncology's revenue or net income, to determine how well the company is positioned to perform in the future. Although Pangaea Oncology investors may analyze each financial statement separately, they are all interrelated. For example, changes in Pangaea Oncology's assets and liabilities are reflected in the revenues and expenses on Pangaea Oncology's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Pangaea Oncology SA. Please read more on our technical analysis and fundamental analysis pages.
Pangaea Oncology, S.A., a medical services company, provides a range of services to cancer patients, and pharmaceutical and biotech clients worldwide. Pangaea Oncology, S.A. was founded in 2007 and is based in Barcelona, Spain. PANGAEA ONCOLOGY operates under Diagnostics Research classification in Spain and is traded on Madrid SE C.A.T.S.. It employs 50 people.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Pangaea Stock
Pangaea Oncology financial ratios help investors to determine whether Pangaea Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Pangaea with respect to the benefits of owning Pangaea Oncology security.